In Early-Stage Medtech, Buyers Are Assessing Your Risk, Not Your Revenue

If there’s one thing that hasn’t changed in the ten years that I’ve been working in medical device M&A, it’s the persistent belief that your Class I/II device must be commercialized, with meaningful revenue, to achieve an exit via M&A. The real problem with that assumption is that it causes founders and boards to kick the exit strategy can down the road, quarter after quarter, year after year, until runway pressure forces it. 

So not only might they have blown right by exit opportunities, they’re now in the unenviable position of attempting to execute a fire sale exit with none of the preparation, prospect relationship building, or de-risking activities required to pull it off. 

It’s maddening because medical device leaders are incredibly intelligent people and they know better. They’re natural planners, project managers, and visionaries. And that last attribute is the heart of the problem. 

Visionaries only see the best for their innovation babies. Were they to face up to the grim odds of making it to market, never mind achieving a blockbuster success, they wouldn’t be able to get out of bed in the morning. They are Don Quixotes, every one, and I love them for it. 

The problem is that the quixotic fervour required to persevere in medical device development when the odds are against you leaves no room for any inkling that your innovation is in fact, an ugly baby that nobody wants. As long as it continues to be a work in progress with ever more features and refinements, the fearful reckoning can be delayed. 

It is the medtech leader’s version of Schrödinger’s cat. 

It’s the emotion that blocks the logic of planning an exit from the beginning. 

And it’s the secret fear that hides behind the premise that only a successfully commercialized medical device has a shot at being acquired. Sadly, that premise ceases to be a cozy hideaway when the funding runs out and the attractiveness of that innovation baby is put to the test under the harshest of circumstances. 

Why do that to yourself, your team, and the medical technology that you’ve developed with such devotion?

The truth is that now, more than ever, strategic buyers are not primarily underwriting revenue. They are underwriting risk.

And if you can overcome your fear of your device being found lacking, you can understand which risks matter most to them, govern yourself accordingly, and materially change your company’s exit profile long before commercialization.

The 5 Risk Milestones That Actually Move Deals

1. Clinical Validation Risk

Have you generated credible data that supports efficacy and safety?

For many strategics, a well-designed pilot or early clinical dataset de-risks adoption more than early revenue does.

Revenue can be transient; validated clinical proof changes category positioning.

2. Regulatory Pathway Certainty

Not “Are you FDA cleared?”

But:

1. Is the pathway defined?
2. Is the predicate clear?
3. Are timelines credible?

Regulatory ambiguity suppresses acquisition interest more than low revenue does; clarity creates optionality.

3. Technical Integration Risk

Strategics ask:

1. Can this integrate into our platform?
2. Does it expand our installed base?
3. Will it require major infrastructure overhaul?

A product that fits cleanly into an existing portfolio can transact earlier than one that requires ecosystem disruption (read: time + expense).

4. Reimbursement Viability

You don’t need a full reimbursement code, but you should have it mapped out in a realistic way.

Buyers want to know:

1. Is reimbursement plausible?
2. Who pays?
3. What economic lever does this pull?

If the economic logic is visible, the revenue can follow post-acquisition.

5. IP Defensibility

Strong IP doesn’t just protect, in many cases it is the strategic value.

A clean, defensible IP position reduces competitive risk for the acquirer.

Why This Matters for Funded Founders

Venture-backed teams often assume:

“We’ll focus on growth, and exit will sort itself out.”

But growth and exit engineering aren't identical strategies.

A company can be:

1. Growing but strategically ambiguous or
2. Pre-commercial but strategically inevitable

The latter often has more exit leverage.

The Shift

Revenue milestones impress boards. Risk milestones impress buyers.

The most successful early exits happen when founders understand both and manage them with intention.

Tomorrow I’ll tell you about a structured planning guide designed to help founders and boards think through these dynamics before they’re under runway pressure. 

Because exit planning is not a last-quarter activity. It’s a strategic design and corporate development choice.